Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions

Agasta Software is engaged in research, development and commercialization of medical devices

Sun Pharmaceutical receives warning letter from USFDA for Halol facility

The Halol facility was placed under Import Alert by USFDA.

Sun Pharmaceutical gets OAI from USFDA for Mohali facility

Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr

It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio

Sun Pharmaceutical Q3FY21 net profit at Rs. 1852.48 Cr

The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.

Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint

The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)

Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata

LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients

Sun Pharma settles patent litigation with Incyte

Briefs: Hikal and Sun Pharma

Sun Pharma gets 8 observations from USFDA for Halol facility